
Ralph Snyderman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10919978/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Personalized Medical Group Visits: A Novel Approach for the Care of Prediabetes. Diabetes Spectrum, 2022, 35, 504-511.	1.0	2
2	Advancing human health in the decade ahead: pregnancy as a key window for discovery. American Journal of Obstetrics and Gynecology, 2020, 223, 312-321.	1.3	13
3	In Reply to Goetz. Academic Medicine, 2020, 95, 972-973.	1.6	0
4	Compassion and Health Care. Academic Medicine, 2019, 94, 1068-1070.	1.6	12
5	An evaluation of mHealth adoption and health self-management in emerging adulthood. AMIA Annual Symposium proceedings, 2019, 2019, 1021-1030.	0.2	1
6	Integration of Personalized Health Planning and Shared Medical Appointments for Patients with Type 2 Diabetes Mellitus. Southern Medical Journal, 2018, 111, 674-682.	0.7	16
7	Health Care Reform in the United States. JAMA - Journal of the American Medical Association, 2016, 316, 1923.	7.4	4
8	Value of Personalized Medicine. JAMA - Journal of the American Medical Association, 2016, 315, 613.	7.4	21
9	Precision medicine: beyond genomics to targeted therapies. Personalized Medicine, 2016, 13, 97-100.	1.5	3
10	Personalized Health Planning in Primary Care Settings. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 27-34.	0.6	6
11	Personalized medicine 2014: has healthcare been transformed?. Personalized Medicine, 2014, 11, 365-368.	1.5	8
12	Patient engagement as a risk factor in personalized health care: a systematic review of the literature on chronic disease. Genome Medicine, 2014, 6, 16.	8.2	134
13	Personalized health care in 2013: a status report on the impact of genomics. North Carolina Medical Journal, 2013, 74, 478-84.	0.2	3
14	Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcare. Personalized Medicine, 2012, 9, 85-91.	1.5	45
15	Personalized Health Care as a Pathway for the Adoption of Genomic Medicine. Journal of Personalized Medicine, 2012, 2, 232-240.	2.5	23
16	Personalized health care: From theory to practice. Biotechnology Journal, 2012, 7, 973-979.	3.5	104
17	Improving Health by Taking It Personally. JAMA - Journal of the American Medical Association, 2010, 303, 363.	7.4	31
18	Commentary: Personalized Health Planning and the Patient Protection and Affordable Care Act: An Opportunity for Academic Medicine to Lead Health Care Reform, Academic Medicine, 2010, 85, 1665-1668	1.6	22

#	Article	IF	CITATIONS
19	The Role of Genomics in Enabling Prospective Health Care. , 2010, , 201-208.		1
20	More About Prospective Health Care. Academic Medicine, 2009, 84, 541.	1.6	0
21	The Role of Genomics in Enabling Prospective Health Care. , 2009, , 378-385.		5
22	Creating meaningful health care reform. Journal of Clinical Investigation, 2009, 119, 2855-2855.	8.2	4
23	Proposal for a new health record to support personalized, predictive, preventative and participatory medicine. Personalized Medicine, 2008, 5, 47-54.	1.5	20
24	Perspective: Prospective Health Care and the Role of Academic Medicine: Lead, Follow, or Get Out of the Way. Academic Medicine, 2008, 83, 707-714.	1.6	37
25	Prospective health care: the second transformation of medicine. Genome Biology, 2006, 7, 104.	9.6	48
26	Prospective care: a personalized, preventative approach to medicine. Pharmacogenomics, 2006, 7, 5-9.	1.3	39
27	The Clinical Researcher—An "Emerging" Species. JAMA - Journal of the American Medical Association, 2004, 291, 882.	7.4	33
28	Prospective medicine: the role for genomics in personalized health planning. Pharmacogenomics, 2004, 5, 1-8.	1.3	31
29	AAP Presidential Address The AAP and the transformation of medicine. Journal of Clinical Investigation, 2004, 114, 1169-1173.	8.2	12
30	AAP Presidential Address The AAP and the transformation of medicine. Journal of Clinical Investigation, 2004, 114, 1169-1173.	8.2	8
31	Interleukin-8-mediated Heterologous Receptor Internalization Provides Resistance to HIV-1 Infectivity. Journal of Biological Chemistry, 2003, 278, 15867-15873.	3.4	52
32	Role of the Cytoplasmic Tails of CXCR1 and CXCR2 in Mediating Leukocyte Migration, Activation, and Regulation. Journal of Immunology, 2003, 170, 2904-2911.	0.8	126
33	Personalized Health Planning. Science, 2003, 300, 549-549.	12.6	41
34	Prospective Medicine: The Next Health Care Transformation. Academic Medicine, 2003, 78, 1079-1084.	1.6	96
35	Integrative Medicine. Archives of Internal Medicine, 2002, 162, 395.	3.8	128
36	Phospholipase C-β2 interacts with mitogen-activated protein kinase kinase 3. Biochemical and Biophysical Research Communications, 2002, 293, 647-652.	2.1	8

#	Article	IF	CITATIONS
37	Function and Regulation of Chemoattractant Receptors. Immunologic Research, 2000, 22, 271-280.	2.9	44
38	Regulation of the Human Chemokine Receptor CCR1. Journal of Biological Chemistry, 2000, 275, 9201-9208.	3.4	67
39	Targeted Disruption of the Leukotriene B4Receptor in Mice Reveals Its Role in Inflammation and Platelet-Activating Factor–Induced Anaphylaxis. Journal of Experimental Medicine, 2000, 192, 433-438.	8.5	167
40	Identification of a Region at the N-Terminus of Phospholipase C-β3 That Interacts with G Protein βγ Subunitsâ€. Biochemistry, 2000, 39, 1800-1806.	2.5	42
41	Clinical Research. Science, 2000, 287, 1927-1927.	12.6	0
42	Chemoattractant Receptors Activate Distinct Pathways for Chemotaxis and Secretion. Journal of Biological Chemistry, 1999, 274, 37087-37092.	3.4	88
43	Chemoattractant Receptor Cross-desensitization. Journal of Biological Chemistry, 1999, 274, 6027-6030.	3.4	236
44	Differential Cross-regulation of the Human Chemokine Receptors CXCR1 and CXCR2. Journal of Biological Chemistry, 1998, 273, 23830-23836.	3.4	132
45	Differential Regulation of Formyl Peptide and Platelet-activating Factor Receptors. Journal of Biological Chemistry, 1998, 273, 11012-11016.	3.4	55
46	Multiple Signaling Pathways of Human Interleukin-8 Receptor A. Journal of Biological Chemistry, 1998, 273, 10690-10695.	3.4	71
47	Regulation of Human Chemokine Receptors CXCR4. Journal of Biological Chemistry, 1997, 272, 28726-28731.	3.4	260
48	Chemoattractant Receptor-induced Phosphorylation of L-selectin. Journal of Biological Chemistry, 1997, 272, 13961-13965.	3.4	48
49	Role of Phospholipase Cl²3 Phosphorylation in the Desensitization of Cellular Responses to Platelet-activating Factor. Journal of Biological Chemistry, 1997, 272, 11706-11709.	3.4	79
50	MECHANISMS OF INFLAMMATION AND LEUKOCYTE ACTIVATION. Medical Clinics of North America, 1997, 81, 1-28.	2.5	87
51	Cross-desensitization Among Receptors for Platelet Activating Factor and Peptide Chemoattractants. Journal of Biological Chemistry, 1996, 271, 28717-28724.	3.4	41
52	Thrombin Primes Responsiveness of Selective Chemoattractant Receptors at a Site Distal to G Protein Activation. Journal of Biological Chemistry, 1996, 271, 3200-3206.	3.4	32
53	Cross-desensitization of Chemoattractant Receptors Occurs at Multiple Levels. Journal of Biological Chemistry, 1995, 270, 27829-27833.	3.4	88
54	Regulation of Human Interleukin-8 Receptor A: Identification of a Phosphorylation Site Involved in Modulating Receptor Functions. Biochemistry, 1995, 34, 14193-14201.	2.5	95

#	Article	IF	CITATIONS
55	Differential regulation of cAMP by endogenous versus transfected fornylpeptide chemoattractant receptors: Implications for Gi-coupled receptor signaling. Biochemical and Biophysical Research Communications, 1992, 183, 1033-1039.	2.1	18
56	Functional high efficiency expression of cloned leucocyte chemoattractant receptor cDNAs. FEBS Letters, 1992, 297, 275-279.	2.8	21
57	Rac1, a low-molecular-mass GTP-binding-protein with high intrinsic GTPase activity and distinct biochemical properties. FEBS Journal, 1992, 206, 537-546.	0.2	47
58	A Synthetic Peptide Homologous to Retroviral Transmembrane Envelope Proteins Depresses Protein Kinase C Mediated Lymphocyte Proliferation and Directly Inactivated Protein Kinase C: A Potential Mechanism for Immunosuppression. Microbiology and Immunology, 1991, 35, 443-459.	1.4	31
59	A soluble inhibitor of T lymphocyte function induced by HIV-1 infection of CD4+ T cells: Characterization of a cellular protein and its relationship to p15E. Cellular Immunology, 1990, 128, 337-352.	3.0	11
60	Isoprenylation of the low molecular mass GTP-binding proteins rac 1 and rac 2: Possible role in membrane localization. Biochemical and Biophysical Research Communications, 1990, 171, 804-812.	2.1	50
61	Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: Immunosuppression, immunogenicity, and relation to immunosuppressive tumor products. Cancer Immunology, Immunotherapy, 1989, 30, 113-118.	4.2	39
62	Substance P primes human neutrophil activation: A mechanism for neurological regulation of inflammation. Biochemical and Biophysical Research Communications, 1989, 161, 520-524.	2.1	128
63	Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation. Immunology Letters, 1988, 19, 7-13.	2.5	58
64	[24] Chemoattractant-induced membrane phenomena of phagocytes. Methods in Enzymology, 1988, 162, 271-279.	1.0	0
65	Chemoattractant Receptors and Signal Transduction Processes. , 1988, , 355-379.		2
66	Signal transduction in cells following binding of chemoattractants to membrane receptors. Virchows Archiv B, Cell Pathology Including Molecular Pathology, 1988, 55, 65-80.	0.2	52
67	Leukocyte Activation by Chemoattractant Receptors: Roles of a Guanine Nucleotide Regulatory Protein and Polyphosphoinositide Metabolism. Clinical Infectious Diseases, 1987, 9, S562-S569.	5.8	25
68	Guanine nucleotide regulatory proteins in receptor-mediated polyphosphoinositide hydrolysis in human leukocytes. Methods in Enzymology, 1987, 141, 261-271.	1.0	9
69	Molecular cloning of a new human G protein Evidence for two Giα-like protein families. FEBS Letters, 1987, 219, 259-263.	2.8	69
70	Human Giprotein α-subunit: deduction of amino acid structure from a cloned cDNA. FEBS Letters, 1987, 211, 160-164.	2.8	81
71	Identification of a novel inositol bisphosphate isomer formed in chemoattractant stimulated human polymorphonuclear leukocytes. Biochemical and Biophysical Research Communications, 1987, 144, 264-270.	2.1	19
72	Role of a Guanine Nucleotide Regulatory Protein in the Polyphosphoinositide Pathway of Leukocyte Activation by Chemoattractant Receptors1. , 1987, , 128-139.		0

#	Article	IF	CITATIONS
73	Regulation of inositol phospholipid and inositol phosphate metabolism in chemoattractant-activated human polymorphonuclear leukocytes. Journal of Cellular Biochemistry, 1987, 35, 345-359.	2.6	21
74	Review of the national arthritis advisory board symposium, "molecular biology: its potential for advancing rheumatology research― Arthritis and Rheumatism, 1987, 30, 1191-1194.	6.7	0
75	Regulation of Leukocyte Responses to Chemoattractants: Role of Receptors, Guanine Nucleotide Regulatory (N) Proteins and Phospholipase C. , 1987, , 277-289.		1
76	A pertussis/choleratoxin-sensitive N protein may mediate chemoattractant receptor signal transduction. Biochemical and Biophysical Research Communications, 1986, 138, 887-894.	2.1	75
77	Model for Leukocyte Regulation by Chemoattractant Receptors: Roles of a Guanine Nucleotide Regulatory Protein and Polyphosphoinositide Metabolism. Journal of Leukocyte Biology, 1986, 40, 785-800.	3.3	176
78	Mechanisms of Inflammation and Leukocyte Chemotaxis in the Rheumatic Diseases. Medical Clinics of North America, 1986, 70, 217-235.	2.5	15
79	Role of guanine nucleotide regulatory protein in polyphosphoinositide degradation and activation of phagocytic leukocytes by chemoattractants. Journal of Cellular Biochemistry, 1986, 32, 59-69.	2.6	24
80	Effects of tumor growth on host defenses. Cancer and Metastasis Reviews, 1986, 5, 15-27.	5.9	20
81	Component Deficiencies 5. The Fifth Component. Chemical Immunology and Allergy, 1986, 39, 271-282.	1.7	0
82	Regulatory Mechanisms of a Chemoattractant Receptor on Human Polymorphonuclear Leukocytes. Clinical Infectious Diseases, 1985, 7, 390-394.	5.8	12
83	Regulation of Mononuclear Leukocyte Function by Transmethylation Reactionsa. Annals of the New York Academy of Sciences, 1985, 451, 256-263.	3.8	0
84	Potential role for a guanine nucleotide regulatory protein in chemoattractant receptor mediated polyphosphoinositide metabolism, Ca++ mobilization and cellular responses by leukocytes. Biochemical and Biophysical Research Communications, 1985, 127, 450-457.	2.1	226
85	The Role of the Neutrophil in the Inflammatory Response. , 1985, , 619-649.		0
86	Immunosuppressive activity of the retroviral envelope protein P 15E and its possible relationship to neoplasia. Trends in Immunology, 1984, 5, 240-244.	7.5	130
87	Similarity between p15E of murine and feline leukaemia viruses and p21 of HTLV. Nature, 1984, 311, 515-515.	27.8	104
88	Transductional Mechanisms of Chemoattractant Receptors on Leukocytes. , 1984, 14, 1-28.		19
89	Pharmacologic manipulation of leukocyte chemotaxis. American Journal of Medicine, 1983, 75, 10-18.	1.5	19
90	Effect of Membrane Fluidizers on the Number and Affinity of Chemotactic Factor Receptors on Human Polymorphonuclear Leukocytes. Microbiology and Immunology, 1983, 27, 961-972.	1.4	13

#	Article	IF	CITATIONS
91	Neoplasia and Mononuclear Phagocyte Function. , 1983, , 193-216.		1
92	Chemoattractant Receptor Affinity Reflects Its Ability to Transduce Different Biological Responses. , 1983, 12, 323-336.		7
93	PHARMACOLOGICAL MANIPULATION OF THE CHEMOTACTIC FACTOR RECEPTOR ON LEUKOCYTES. , 1983, , 211-219.		1
94	Transmethylation reactions regulate affinity and functional activity of chemotactic factor receptors on macrophages. Cell, 1982, 28, 107-114.	28.9	61
95	The oligopeptide chemotactic factor receptor on human polymorphonuclear leukocyte membranes exists in two affinity states. Biochemical and Biophysical Research Communications, 1982, 106, 442-449.	2.1	147
96	Inhibitors of Monocyte Responses to Chemotaxins are Associated with Human Neoplasms. Advances in Experimental Medicine and Biology, 1982, 155, 343-352.	1.6	4
97	SPECIFIC RECEPTORS AND TRANSMETHYLATION REACTIONS ARE REQUIRED FOR LEUKOCYTE CHEMOTAXIS. , 1982, , 67-86.		0
98	QUANTITATION OF THE INFLAMMATORY ACCUMULATION OF MONONUCLEAR PHAGOCYTES IN VIVO. , 1981, , 959-968.		2
99	Monocyte Responsiveness to Chemotactic Stimuli is a Property of a Subpopulation of Cells that can Respond to Multiple Chemoattractants. Journal of Clinical Investigation, 1981, 67, 60-68.	8.2	102
100	Mechanisms of Nonspecific Host Resistance. , 1981, , 101-114.		0
101	Depression of Murine Macrophage Accumulation by Low-Molecular-Weight Factors Derived From Spontaneous Mammary Carcinomas2. Journal of the National Cancer Institute, 1980, 65, 829-834.	6.3	32
102	An Inherited Abnormality of Neutrophil Adhesion. New England Journal of Medicine, 1980, 302, 1163-1168.	27.0	304
103	Role of transmethylation reactions in cellular motility and phagocytosis. Molecular Immunology, 1980, 17, 209-218.	2.2	42
104	Biochemical and Biological Aspects of Leukocyte Chemotactic Factors. , 1980, , 1-19.		0
105	Deficiency of the fifth component of complement in human subjects. American Journal of Medicine, 1979, 67, 638-645.	1.5	67
106	Chronic mucocutaneous candidiasis. American Journal of Medicine, 1979, 67, 948-959.	1.5	60
107	Quantification of Lymphokine Production in Human Disease. , 1979, , 181-208.		1
108	The Role of Macrophages in the Rheumatic Diseases. Clinics in Rheumatic Diseases, 1978, 4, 499-515.	1.3	7

#	Article	IF	CITATIONS
109	Disorders of Leukocyte Chemotaxis. Pediatric Clinics of North America, 1977, 24, 377-393.	1.8	14
110	Generalized Microsporum audouinii infection and depressed cellular immunity associated with a missing plasma factor required for lymphocyte blastogenesis. American Journal of Medicine, 1977, 63, 991-1000.	1.5	48
111	Characterization of human chemotactic lymphokine production induced by mitogens and mixed leukocyte reactions using a new microassay. Cellular Immunology, 1977, 30, 225-235.	3.0	35
112	Influenza-induced depression of monocyte chemotaxis: Reversal by levamisole. Cellular Immunology, 1977, 32, 234-238.	3.0	31
113	Cellular serine proteinase induces chemotaxis by complement activation. Nature, 1977, 269, 521-522.	27.8	41
114	Biologic Aspects of Leukocyte Chemotaxis. , 1977, , 159-181.		0
115	Prostaglandins and inflammation: Enhancement of monocyte chemotactic responsiveness by prostaglandin E2. Prostaglandins, 1976, 12, 415-426.	1.2	39
116	Chemotaxis of Macrophages. , 1976, , 323-348.		43
117	Augmentation of human monocyte chemotactic response by levamisole. Nature, 1976, 261, 136-137.	27.8	68
118	DEFECTIVE MACROPHAGE MIGRATION PRODUCED BY NEOPLASMS: IDENTIFICATION OF AN INHIBITOR OF MACROPHAGE CHEMOTAXIS11Supported in part by National Cancer Institute Contract No. NO1 CP 33313 and National Institute of Dental Research Grant 5 RO1 DE 03738-03 , 1976, , 49-65.		19
119	ABNORMALITIES OF LEUKOCYTE CHEMOTAXIS IN HUMAN DISEASE. Annals of the New York Academy of Sciences, 1975, 256, 386-401.	3.8	44
120	Defective Monocyte Function in Patients With Genitourinary Carcinoma 2. Journal of the National Cancer Institute, 1975, 55, 1047-1054.	6.3	76
121	Production of Chemotactic Factor and Lymphotoxin by Human Leukocytes Stimulated with Herpes Simplex Virus. Infection and Immunity, 1974, 10, 111-115.	2.2	57
122	Abnormalities of Chemotactic Lymphokine Synthesis and Mononuclear Leukocyte Chemotaxis in Wiskott-Aldrich Syndrome. Journal of Clinical Investigation, 1974, 54, 486-493.	8.2	95
123	Immunological Mechanisms of Periodontal Tissue Destruction. Journal of the American Dental Association, 1973, 87, 1020-1026.	1.5	14
124	Defective Mononuclear Leukocyte Chemotaxis: A Previously Unrecognized Immune Dysfunction. Annals of Internal Medicine, 1973, 78, 509.	3.9	99
125	Role for Endotoxin and Complement in Periodontal Tissue Destruction. Journal of Dental Research, 1972, 51, 356-361.	5.2	47
126	Further Characterization of a Factor From Endotoxin-Treated Serum which Releases Histamine and Heparin from Mast Cells. Infection and Immunity, 1972, 5, 909-914.	2.2	15

#	Article	IF	CITATIONS
127	Effect of C4 Depletion on the Utilization of the Terminal Components of Guinea-pig Complement by Endotoxin. Nature: New Biology, 1971, 231, 152-154.	4.5	14
128	A Chemotactic Factor for Mononuclear Leukocytes. Experimental Biology and Medicine, 1971, 138, 387-390.	2.4	104
129	Chemotaxis of Inflammatory Cells. Journal of Dental Research, 1971, 50, 304-308.	5.2	5
130	BIOLOGICAL ACTIVITY OF COMPLEMENT IN VIVO. Journal of Experimental Medicine, 1971, 134, 1131-1143.	8.5	198
131	Immunologic Reactions and Periodontal Inflammation. Journal of Dental Research, 1970, 49, 256-261.	5.2	98
132	Factors from Saliva and Oral Bacteria, Chemotactic for Polymorphonuclear Leukocytes: Their Possible Role in Gingival Inflammation. Journal of Periodontology, 1970, 41, 71-80.	3.4	116
133	Polymorphonuclear Leukocyte Chemotactic Activity in Rabbit Serum and Guinea Pig Serum Treated with Immune Complexes: Evidence for C5a as the Major Chemotactic Factor. Infection and Immunity, 1970, 1, 521-525.	2.2	164
134	Histamine-Releasing Factor Generated by the Interaction of Endotoxin with Hamster Serum. Infection and Immunity, 1970, 2, 462-467.	2.2	25
135	Factors from Saliva and Oral Bacteria, Chemotactic for polymorphonuclear Leukocytes: Their Possible Role in Gingival Inflammation. Journal of Periodontology, 1970, 41, 71-80.	3.4	12
136	Reaction of a Cobra Venom Factor with Guinea Pig Complement and Generation of an Activity Chemotactic for Polymorphonuclear Leukocytes. Experimental Biology and Medicine, 1969, 131, 203-207.	2.4	63
137	Significance of Complement to the Mechanism of Action of Endotoxin. Current Topics in Microbiology and Immunology, 1969, 50, 37-77.	1.1	117